Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)

Inclusion Criteria

• To be eligible for the study, the following must be answered "YES" or not applicable, as appropriate for the study subject:
• Is the subject a male or female at least 5 years-of-age?
• Is the subject or legal guardian able to give written informed consent or assent, as appropriate?
• Does the subject have a diagnosis of CL in at least one lesion by at least one of the following methods: 1) positive culture for promastigotes, or 2) microscopic identification of amastigotes in stained lesion tissue.
• Does the subject have at least one ulcerative lesion ≥ 1 cm and ≤ 5 cm, that meets the criteria for an index lesion?
• Is the subject willing to forego other forms of treatments for CL including other investigational treatments during the study?
• In the opinion of the investigator, is the subject (or their legal guardian) capable of understanding and complying with the protocol?
• If female and of child-bearing potential, did the subject have a negative pregnancy test during screening and agree to use an acceptable method of birth control during the treatment phase and for 1 month after treatment is completed?
• Does the subject have adequate venous access for blood draws?

Exclusion Criteria

To be eligible for the study, the following must be answered "NO" or not applicable as appropriate for the study subject:

• Does the subject have only a single lesion whose characteristics include any of the following: verrucous or nodular lesion (non-ulcerative), lesion 10 lesions?
• Is the subject a female who is breast-feeding?
• Does the subject have an active malignancy or history of solid, metastatic or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed?
• Does the subject have significant organ abnormality, chronic disease such as diabetes, severe hearing loss, evidence of renal or hepatic dysfunction, or creatinine greater than 15%, or aspartate aminotransferase (AST), or alanine aminotransferase (ALT) greater than 1.5 times the above the upper limit of normal (ULN) as defined by the clinical laboratory defined normal ranges?
• Has the subject received treatment for leishmaniasis including any medication with pentavalent antimony including sodium stibogluconate (Pentostam), meglumine antimoniate (Glucantime); amphotericin B (including liposomal amphotericin B and amphotericin B deoxycholate); or other medications containing paromomycin (administered parenterally or topically) or methylbenzethonium chloride (MBCL); gentamicin; fluconazole; ketoconazole; pentamidine; miltefosine, azithromycin or allopurinol that was completed within 8 weeks of starting study treatments?
• Does the subject have a history of known or suspected hypersensitivity or idiosyncratic reactions to aminoglycosides?
• Does the subject have any other topical disease/condition which would interfere with the objectives of this study?